Karin Brandell

Karin Brandell

Auto-generated profile, based on publicly available information

Karin Brandell

Department of Women's and Children's Health Karolinska Institutet Stockholm Sweden

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2024 in New England Journal of Medicine
Verified
Journal Article
Closed access
KBKarin Brandell
Karin Brandell
TJTagrid Jar-Allah
Tagrid Jar-Allah
JRJohn Reynolds-Wright
John Reynolds-Wright
HKHelena Kopp Kallner
Helena Kopp Kallner
HHHelena Hognert
Helena Hognert
KGKristina Gemzell-Danielsson
Kristina Gemzell-Danielsson
Medication abortion, with a combination of mifepristone and misoprostol, is highly effective and safe. However, there is insufficient evidence on efficacy and safety at very early gestations before a pregnancy can be visualized with ultrasonography. We conducted a multicenter, noninferiority, randomized, controlled trial involving women requesting medication abortion at up to 42 days of gestation with an unconfirmed intrauterine pregnancy on ultrasound examination (visualized as an empty cavity or a sac-like structure without a yolk sac or embryonic pole). Participants were randomly assigned to either immediate start of abortion (early-start group) or standard-care treatment delayed until intrauterine pregnancy was confirmed (standard group). The primary outcome was complete abortion. The noninferiority margin was set at 3.0 percentage points for the absolute between-group difference. In total, 1504 women were included at 26 sites in nine countries and were randomly assigned to the early-start group (754 participants) or the standard group (750 participants). In an intention-to-treat analysis, a complete abortion occurred in 676 of 710 participants (95.2%) in the early-start group and in 656 of 688 (95.3%) in the standard group; the absolute between-group difference was -0.1 percentage points (95% confidence interval, -2.4 to 2.1). Ectopic pregnancies occurred in 10 of 741 participants (1.3%) in the early-start group and in 6 of 724 (0.8%) in the standard group, with one rupture before diagnosis (early-start group). Serious adverse events occurred in 12 of 737 participants (1.6%) in the early-start group and in 5 of 718 (0.7%) in the standard group (P = 0.10); the majority were uncomplicated hospitalizations for treatment of ectopic pregnancy or incomplete abortion. Medication abortion before confirmed intrauterine pregnancy was noninferior to standard, delayed treatment with respect to complete abortion. (Funded by the Swedish Research Council and others; VEMA EudraCT number, 2018-003675-35; ClinicalTrials.gov number, NCT03989869.).

12 October 2021 in BMJ Sexual & Reproductive Health
Verified
Journal Article
Open access
PDF file
KBKarin Brandell
Karin Brandell
HVHannah Vanbenschoten
Hannah Vanbenschoten
MPMirella Parachini
Mirella Parachini
RGRebecca Gomperts
Rebecca Gomperts
KGKristina Gemzell-Danielsson
Kristina Gemzell-Danielsson
Introduction Induced abortion is legal in Italy but with restrictions. The online abortion provider Women on Web (WoW) serves as an alternative way to access abortion. The COVID-19 pandemic has affected sexual and reproductive health worldwide. Italy was one of the first countries hit by the pandemic and imposed strict lockdown measures. We aimed to understand why women requested WoW abortion in Italy and how this was affected by the pandemic. Methods We conducted an observational study analysing requests made to WoW before and during the pandemic. We analysed 778 requests for medical abortion from Italy between 1 March 2019 to 30 November 2020 and compared the characteristics of requests submitted before and during the pandemic. We also performed subgroup analysis on teenagers and COVID-19-specific requests. Results There was an increase in requests during the COVID-19 pandemic compared with the previous year (12% in the first 9 months). The most common reasons for requesting a telemedicine abortion through WoW were privacy-related (40.9%); however, this shifted to COVID-19-specific (50.3%) reasons during the pandemic. Requests from teenagers (n=61) were more frequently made at later gestational stages (p=0.003), had a higher prevalence of rape (p=0.003) as the cause of unwanted pregnancies, and exhibited less access to healthcare services compared with adult women. Conclusions There was an increase in total demand for self-managed abortion during the pandemic and reasons for requesting an abortion changed, shifting from privacy-related to COVID-19-specific reasons. This study also highlighted the uniquely vulnerable situation of teenagers with unwanted pregnancies seeking self-managed abortion.


2 July 2025 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Open access
FGFrida Gyllenberg
Frida Gyllenberg
KBKarin Brandell
Karin Brandell
TJTagrid Jar‐Allah
Tagrid Jar‐Allah
HKHelena Kopp Kallner
Helena Kopp Kallner
JRJohn Reynolds‐Wright
John Reynolds‐Wright
KGKristina Gemzell-Danielsson
Kristina Gemzell-Danielsson
Introduction: Little is known regarding the impact of gestation on pain, bleeding duration, and satisfaction in early medical abortion (termination of pregnancy). This study aimed to determine if pain experience, bleeding duration, and overall satisfaction with medical abortion differed across four ultrasound‐defined categories of early pregnancy.Material and Methods: This is a secondary analysis of the multicenter VEMA‐trial, a randomized clinical trial on the efficacy and safety of very early medical abortion before confirming pregnancy location (the VEMA‐trial, EudraCT 2018‐003675‐35, ClinicalTrials.gov NCT03989869). The present study included participants with normally developing pregnancies and known abortion outcomes, including complete abortion, incomplete abortion, and ongoing pregnancy, that is, pregnancy still progressing after medical abortion. Participants were grouped by ultrasound findings at the time of abortion into pregnancy of unknown location, early, normally sited pregnancy (empty sac), and normally sited pregnancy with visible yolk sac or visible embryo. Pain experience was measured on the 0–10 numeric rating scale (higher values for more pain), duration of bleeding in days, and satisfaction on a 0–6 scale (higher values indicating greater satisfaction).Results: Altogether 1253 participants were included: 18% (224 participants) with pregnancy of unknown location, 38% (476) with early, normally sited pregnancy, 24% (301) with visible yolk sac, and 20% (252) with visible embryo. Pain scores were lowest in the pregnancy of unknown location group (mean 5.2 ± SD 2.3) and highest in the pregnancy with visible embryo group (6.2 ± 2.4). Bleeding duration was shortest for pregnancies of unknown location (4.9 ± 3.2) and longest for those with visible embryo (7.5 ± 5.3). Mean satisfaction was over 5 in all groups, highest in early, normally sited pregnancies (5.7 ± 0.7). In regression analyses, both pain scores and bleeding duration increased with advancing ultrasound findings. The pregnancy of unknown location group reported the least pain (1.02 points lower, 95% Confidence Interval [CI] −1.46 to −0.57) and the shortest bleeding duration (34% shorter, incidence rate ratio 0.66, 95% CI 0.61 to 0.71) compared to pregnancies with visible embryo.Conclusions: More advanced ultrasound findings are associated with higher pain scores and longer bleeding duration in very early medical abortion, whereas satisfaction is high across ultrasound‐defined categories.

22 December 2021 in BMJ Sexual & Reproductive Health
Verified
Journal Article
Open access
PDF file
MGMonserrat Vasquez Ladron de Guevara
Monserrat Vasquez Ladron de Guevara
OIOnaedo Ilozumba
Onaedo Ilozumba
KBKarin Rebecka Brandell
Karin Rebecka Brandell
KGKristina Gemzell-Danielsson
Kristina Gemzell-Danielsson
RGRebecca Gomperts
Rebecca Gomperts